Clinical Trial Update: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 trial of cannabidiol oral solution as adjunctive therapy for Lennox-Gastaut Syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lennox-gastaut Syndrome

Drugs mentioned

• Cannabidiol Oral Solution (cannabidiol)

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Lennox-Gastaut Syndrome | Phase 3 | Status: WITHDRAWN